Navigation Links
OMT announces a breakthrough in the development of a novel human antibody platform
Date:7/23/2009

Palo Alto, CA: July 23, 2009 Open Monoclonal Technology, Inc. (OMT), in collaboration with Sangamo BioSciences, Inc. (NASDAQ, SGMO), Sigma-Aldrich Corporation (NASDAQ: SIAL), The Medical College of Wisconsin, and INSERM, today announced the creation of the first targeted knockout rats as detailed in "Knockout Rats Produced via Embryo Microinjection of Designed Zinc Finger Nucleases," published in the July 24th issue of Science. The creation of rats with permanent, heritable genetic mutations is a critical milestone in the development of OMT's novel human monoclonal antibody platform.

"Creating a knockout rat was the biggest challenge OMT faced", said Dr. Roland Buelow, CEO of OMT and senior author of the paper. "Inactivation of endogenous rat antibody expression is essential for human antibody expression in genetically engineered animals. To solve this problem, we explored a new application for Zinc Finger Nuclease (ZFN) technology, which enabled a technique that could revolutionize the genetic engineering of animals."

In the study, OMT scientists and its collaborators used ZFNs developed by Sangamo BioSciences, Inc. to knockout a gene encoding rat immunoglobulin. The mutations in rat immunoglobulin caused no off-target effects in other genes, and offspring of the ZFN-edited rats carried the mutated genes. Together, these results demonstrate the ability to generate heritable, specific and permanent modifications in a mammal using standard microinjection techniques and engineered ZFNs in early-stage embryos.

With antibody sales expected to reach $50 billion within five years, many companies have entered the biologics market through acquiring antibody technologies or licensing/fee for service arrangements. Currently, the mouse is the only genetically engineered animal commercially available for the generation of human monoclonal antibodies, and many targets are licensed already. The expense and limitations of the mouse technology create an opportunity for OMT and its new monoclonal antibody platform with unrestricted development options.

OMT's human antibody technology is the result of an improved understanding of B-cell development and a novel approach to the inactivation of endogenous antibody expression described in the "Science" article. Previously, it took either embryonic stem cells or nuclear transfer cloning -- techniques that are not available for the genetic engineering of rats to create a knockout, OMT used a new ZFN-mediated technique to generate immunoglobulin knockout rats. ZFNs are engineered proteins that induce double-strand breaks at specific sites in an organism's DNA. Such double-strand breaks stimulate the cell's natural DNA-repair pathways and can result in site- specific changes in the DNA sequence. Up to now, ZFNs have been used to edit specific genes in fruit flies, worms (C. elegans), cultured cells and zebrafish embryos, but this is the first example of successful, permanent, heritable gene-editing in a mammal.


'/>"/>

Contact: Dr. Roland Buelow
rbuelow@omtinc.net
650-224-6835
Open Monoclonal Technology, Inc.
Source:Eurekalert

Related biology technology :

1. Northwest Biotherapeutics Announces Plans to De-list From AIM and Consolidate its Stock Market Listing in U.S.
2. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present Second Quarter 2009 Financial Results
4. Cell Therapeutics, Inc. Announces Pricing of Public Offering of Common Stock and Warrants
5. Response Genetics Announces $4 Million Private Placement
6. Sangamo BioSciences Announces Second Quarter 2009 Conference Call and Webcast
7. Global One Consulting Announces Exclusive Contract to Expand Saigene Biotech, Inc. Sales in Emerging Markets
8. NewBridge Pharmaceuticals Announces Licensing of Pylera(R) for Middle East, Africa, Turkey & Caspian Region
9. Thomson Reuters Announces 2009 Edition of the CMR International Pharmaceutical R&D Factbook
10. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
11. Human Genome Sciences Announces New Order for Raxibacumab (ABthrax(TM)) from U.S. Government
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... (PRWEB) , ... October 11, 2017 , ... Personal eye wash is a basic first ... eye at a time. So which eye do you rinse first if a dangerous substance ... Plum Duo Eye Wash with its unique dual eye piece. , “Whether its ...
(Date:10/11/2017)... and LAGUNA HILLS, Calif. , Oct. ... Cancer Research, London (ICR) and University ... SKY92, SkylineDx,s prognostic tool to risk-stratify patients with multiple myeloma ... MUK nine . The University of Leeds ... partly funded by Myeloma UK, and ICR will perform the ...
(Date:10/10/2017)... ... October 10, 2017 , ... San Diego-based team building and ... rebranding initiative announced today. The bold new look is part of a transformation ... moves into a significant growth period. , It will also expand its service offering ...
(Date:10/10/2017)... 10, 2017 International research firm Parks Associates announced ... at the TMA 2017 Annual Meeting , October 11 in ... residential home security market and how smart safety and security products impact ... Parks Associates: Smart Home ... "The residential security market has ...
Breaking Biology Technology:
(Date:4/3/2017)... WASHINGTON , April 3, 2017 /PRNewswire-USNewswire/ ... single-cell precision engineering platform, detected a statistically ... cell product prior to treatment and objective ... highlight the potential to predict whether cancer ... prior to treatment, as well as to ...
(Date:3/29/2017)... the health IT company that operates the largest health ... today announced a Series B investment from BlueCross BlueShield ... investment and acquisition accelerates higi,s strategy to create the ... activities through the collection and workflow integration of ambient ... secures data today on behalf of over 36 million ...
(Date:3/24/2017)... DUBLIN , Mar 24, 2017 Research ... Vehicle Access System Market Analysis & Trends - Industry Forecast to ... ... poised to grow at a CAGR of around 15.1% over the ... This industry report analyzes the market estimates and forecasts for ...
Breaking Biology News(10 mins):